Eprenetapopt is a Mutant TP53 Reactivator for Pancreatic Cancer Research
Pancreatic cancer accounts for the second highest number of cancer deaths. The 5-year survival rate for pancreatic cancer is very low. Approximately 85% of pancreatic cancers are pancreatic ductal adenocarcinomas…